|
|||||||
| Politics, World Affairs Change up the chat and talk about important issues of the world |
 |
| Thread Tools |
|
#11
|
|||
|
|||
Only 8 people
The Moderna study were results reported effective with only 8 people
Only 8 people mRNA-1273 is a experimental vaccine messenger RNAs (mRNAs) are experimental and a completely new type of vaccine Moderna therapy is mRNA-1273 Moderna Therapeutics in Cambridge, Massachusetts, from their own published White Paper written by them, where Moderna gives a development time of “4 to 7 years” for the mRNA experimental vaccine https://www.modernatx.com/sites/defa...50317_v8_4.pdf The Moderna vaccine Phase 1 study was limited and it was a small study with “only eight volunteers and all eight people made antibodies in six weeks” Phase 3 in the study starts in July COVID-19 is caused by a betacoronavirus called SARS-CoV-2 Moderna’s platform-based therapy mRNA-1273 was recruited for a Phase I clinical trial. Moderna’s approach is instead of using dead or weakened viruses like traditional vaccines, they are using messenger RNAs (mRNAs). Once administered, these mRNAs will direct a vaccine recipient’s cells to produce proteins that mimic a “spike protein” that SARS-CoV-2 uses to gain entry into host cells. The hope is that these proteins will elicit an immune response that will protect the recipient from future infection with the COVID-19 virus Moderna has already produced clinical trial-ready batches of its product and is simultaneously conducting necessary pre-clinical studies in human volunteers for safety trials The investigational vaccine was developed using a genetic platform called (mRNA) messenger RNA. The investigational vaccine directs the body’s cells to express a virus protein that it is hoped will elicit a robust immune response. The mRNA-1273 vaccine is currently in its first human Phase 1 trial to examine its effectiveness mRNA is a whole new type of vaccine Vaccines work by training the body to recognize and respond to the proteins produced by disease-causing organisms, such as a virus. Traditional vaccines are made up of small or inactivated doses of the whole disease-causing organism, or the proteins that it produces, which are introduced into the body to provoke the immune system into mounting a response mRNA vaccines, in contrast, trick the body into producing some of the viral proteins itself. They work by using mRNA, or messenger RNA, which is the molecule that essentially puts DNA instructions into action. Inside a cell, mRNA is used as a template to build a protein. ‘An mRNA is basically like a pre-form of a protein and its sequence encodes what the protein is basically made of later on’ To produce an mRNA vaccine, scientists produce a synthetic version of the mRNA that a virus uses to build its infectious proteins. This mRNA is delivered into the human body, whose cells read it as instructions to build that viral protein, and therefore create some of the virus’s molecules themselves. These proteins are solitary, so they do not assemble to form a virus. The immune system then detects these viral proteins and starts to produce a defensive response to them There is still a lot of work to be done to understand this response, the length of the protection it could give and whether there are any downsides Outstanding questions include whether the proteins that have been chosen for the vaccine are the right ones to prevent a coronavirus infection in the body, how targeted the immune response is to this particular coronavirus, whether it causes side-effects such as increased inflammatory responses like redness and swelling or aggravates the disease, and how long any immunity would last |
|
#12
May 19th, 2020
|
|||
|
|||
|
"There is still a lot of work to be done to understand this response, the length of the protection it could give and whether there are any downsides
Outstanding questions include whether the proteins that have been chosen for the vaccine are the right ones to prevent a coronavirus infection in the body, how targeted the immune response is to this particular coronavirus, whether it causes side-effects such as increased inflammatory responses like redness and swelling or aggravates the disease, and how long any immunity would last" The above quote from wormgob's above post, appear to be his questions, not a statement from the mRNA vaccine maker Moderna. A clever name for the company-- MODE--RNA becomes Moderna. Check this one out for the 'DNA'based vaccine being tested: https://www.inovio.com/our-focus-ser...ents/covid-19/ Bill and Melinda Gates Foundation is backing both of these. Neither one requires refrigeration of product as in past standard vaccines. Human trials are ongoing with both and ability to produce and distribute once efficacy is proven will be key. |
|
#13
May 19th, 2020
|
|||
|
|||
|
Posting Press Releases
Why hype Biotechnology Pharmaceuticals Moderna and Inovio ?
Why does marsean “only” post “press releases” written by Big Pharma Biotechs Inovio or Moderna ? Moderna sold $1.3 billion worth of stock on Monday at a price of $80 a share. That’s a fourfold rise from price where the biotech’s stock started the year and a market value of $30 billion for a company that has yet to sell its first product Moderna stock shares have surged 297% since the beginning of the year What investors are betting on, for Moderna developing a vaccine against the SARS-CoV-2 virus, is that a third of the developed world’s population will get vaccinated every year. That could amount to over $10 billion in annual business at an estimated price of $30 per vaccination. At higher prices Covid-19 vaccine revenue would be even bigger Moderna could start charging $125 per treatment in the U.S. market and raise that price over time to $200. Most of the world’s health-care systems are government-run so that pricing abroad will be a fraction of America’s pricing Estimate about only 30% of America’s head count getting vaccinated each year or some 100 million treatments a year. Put a price from $30 to $130 per vaccination treatment on those numbers and you get up to to $13 billion in U.S. sales for Moderna Inovio stock price also rocketed and is close behind |
|
#14
May 19th, 2020
|
|||
|
|||
|
118 Covid-19 vaccines in development worldwide
Scientists have at least 118 Covid-19 vaccine candidates in development worldwide
Eight of those have already entered early clinical trials in people. At least two have protected a small number of monkeys from infection with the novel coronavirus, SARS-CoV-2, that causes COVID-19 Of the 118 currently under development for COVID-19 there are 26 that are using experimental DNA or RNA based vaccines Most vaccine candidates don’t make it as more than 90 percent fail No RNA and DNA vaccines have ever been approved for humans — for any virus DNA vaccines have been in development for two decades and struggle to cause a strong immune response to a virus RNA vaccines are a newer approach and delivering them to the right cells is a challenge Johnson & Johnson are taking a different approach using a non-infectious version of an adenovirus, a common cold virus, to shuttle DNA for an antigen into the body's cells In China, biotechnology company CanSino Biologics has a viral vector-based vaccine candidate. The strategy packages genetic material from SARS-CoV-2 into a weakened adenovirus strain. This company has already started to work on a Phase 2 trial Beijing-based Sinovac Biotech with its whole-virus inactivated SARS-CoV-2 vaccine candidate is in its Phase 1 clinical trials in humans Researchers at Oxford University are off to a good start with their viral vector-based vaccine candidate. They have packaged the SARS-CoV-2 spike protein in a weakened adenovirus similar to CanSino Biologics approach. Like Sinovac Biotech their vaccine at Oxford University has protected a small number of monkeys in early lab experiments. Oxford researchers began dosing human trial participants There are many ways to try to train the immune system to fight off germs or specific elements of germs such as SARS-CoV-2 or the SARS-CoV-2 spike proteins 6 Vaccine Platforms Live-attenuated vaccine Inactivated vaccine Viral vector-based vaccine Subunit vaccines RNA vaccines DNA vaccines Here is the current list of all 118 Covid-19 (coronavirus target SARS-CoV2) candidate vaccines in development worldwide with their current stage of clinical evaluation (Phase 1 - Phase 2) as of May 15, 2020 Listed by Developer, Platform, and Type of Candidate Vaccine with links to the scientific research studies of the only 8 developers with candidate vaccines currently now in clinical trials in Phase 1 - Phase 2 3 of the 8 are RNA - DNA vaccines BioNTech - Fosun Pharma - Pfizer Inovio Pharmaceuticals Sinovac Biotech University of Oxford Beijing Institute of Biological Products - Sinopharm Moderna - NIAID Wuhan Institute of Biological Products - Sinopharm CanSino Biological Inc. - Beijing Institute of Biotechnology 8 candidate vaccines in clinical evaluation 110 candidate vaccines in preclinical evaluation Here’s the complete list: https://www.who.int/docs/default-sou...&download=true |
|
#15
May 20th, 2020
|
|||
|
|||
|
worm that's a lot of digging on pharma and vaccine development. But you are off the subject of the thread, of Newsom's Stay at Home Order. There will have to be progress for opening up again to avoid long term damage in CA economy. No doubt it's work in progress or else the lawsuits may take care of the "problem". Nothing is surprising at this point.
|
|
#16
May 30th, 2020
|
|||
|
|||
|
Newsom and Pelosi
|
|
| Bookmarks |
|
|
